Muhsen, I., Advani, A. S., Roloff, G. W., Jeyakumar, N., Miller, K., Zhang, A., … Hill, L. (2024). Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above. In Blood (Vol. 144, pp. 523–523). American Society of Hematology. https://doi.org/10.1182/blood-2024-210682

Muhsen, Ibrahim, Anjali S. Advani, Gregory W. Roloff, Nikeshan Jeyakumar, Katharine Miller, Amy Zhang, Katherine C. Sutherland, et al. “Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above.” In Blood, 144:523–523. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-210682.

Muhsen I, Advani AS, Roloff GW, Jeyakumar N, Miller K, Zhang A, et al. Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above. In: Blood. American Society of Hematology; 2024. p. 523–523.

Muhsen, Ibrahim, et al. “Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 523–523. Crossref, doi:10.1182/blood-2024-210682.

Muhsen I, Advani AS, Roloff GW, Jeyakumar N, Miller K, Zhang A, Sutherland KC, Grunwald MR, Kota VK, Boccucci J, Ulrickson M, Sasine J, Aldoss I, Othman T, Vasu S, Reshef R, Luskin MR, Chen EC, Lin C, Langston A, Cassaday RD, Kopmar NE, Tsai SB, O’Connor TE, Hilal T, Faramand R, Park JH, Valtis YK, Solh MM, Bezerra E, Leonard JT, Dekker SE, Majhail N, Battiwalla M, Malik SA, Mathews J, Shaughnessy P, Mountjoy L, Hoeg RT, Oliai CH, Gupta V, Koura D, Dykes KC, Logan AC, Kumaran MV, Stock W, Schwartz M, Bachanova V, Tracy S, O’Dwyer KM, Moore J, Lee CJ, Bobillo MSO, Frey N, Connor MP, Jamy O, Daunov M, Ladha A, Yaghmour G, Jackson C, Irrizary Gatell V, Oluwole OO, Dholaria B, Pullarkat V, Merchant A, Shah BD, Muffly L, Hill L. Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above. Blood. American Society of Hematology; 2024. p. 523–523.